Mesenchymal Stromal Cell Therapy in Lung Transplantation
Bioengineering · 17.06.2023 · 10 (6) · 728
DOI: 10.3390/bioengineering10060728 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 17.06.2023. Verfasst von Antti I Nykänen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Latner Thoracic Surgery Research Laboratories, Toronto General Research Hospital Institute, University Health Network, Toronto, ON M5G 1L7, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The study was Supported by Canadian Institutes of Health Research (CIHR) Open Operating Grant, Canadian Institutes of Health Research (CIHR), Sigrid Juselius Foundation Fellowship Grant.
Abstract (Originalsprache)
Lung transplantation is often the only viable treatment option for a patient with end-stage lung disease. Lung transplant results have improved substantially over time, but ischemia-reperfusion injury, primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction (CLAD) continue to be significant problems. Mesenchymal stromal cells (MSC) are pluripotent cells that have anti-inflammatory and protective paracrine effects and may be beneficial in solid organ transplantation. Here, we review the experimental studies where MSCs have been used to protect the donor lung against ischemia-reperfusion injury and alloimmune responses, as well as the experimental and clinical studies using MSCs to prevent or treat CLAD. In addition, we outline ex vivo lung perfusion (EVLP) as an optimal platform for donor lung MSC delivery, as well as how the therapeutic potential of MSCs could be further leveraged with genetic engineering.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Latner Thoracic Surgery Research Laboratories, Toronto General Research Hospital Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Department of Cardiothoracic Surgery, Helsinki University Hospital and University of Helsinki, FI-00029 Helsinki, Finland.
ORCID-Profile: Antti I Nykänen, Mingyao Liu
Förderung
- The study was Supported by Canadian Institutes of Health Research (CIHR) Open Operating Grant
- Canadian Institutes of Health Research (CIHR)
- Sigrid Juselius Foundation Fellowship Grant
Zitieren
APA
Nykänen, A. I., Liu, M., & Keshavjee, S. (2023). Mesenchymal Stromal Cell Therapy in Lung Transplantation. Bioengineering, 10(6), 728. https://doi.org/10.3390/bioengineering10060728
Vancouver
Nykänen AI, Liu M, Keshavjee S. Mesenchymal Stromal Cell Therapy in Lung Transplantation. Bioengineering. 2023;10(6):728. doi:10.3390/bioengineering10060728
BibTeX
@article{Nyknen2023,
author = {Nykänen, Antti I and Liu, Mingyao and Keshavjee, Shaf},
title = {Mesenchymal Stromal Cell Therapy in Lung Transplantation},
journal = {Bioengineering},
year = {2023},
volume = {10},
number = {6},
pages = {728},
doi = {10.3390/bioengineering10060728}
}
EUVIMED